Incyte to acquire Escient Pharmaceuticals for over $750m
Incyte has agreed to acquire Escient Pharmaceuticals and its two potential first-in-class oral Mas-related G protein-coupled receptor (MRGPR) antagonists in a deal worth over $750m. Escient Pharmaceuticals is